- Hepatitis C Virus and Antiviral Drug Resistance
-
Kim S, Han KH, Ahn SH
- KMID: 2412093
- Gut Liver.
- 2016 Nov;10(6):890-895.
- doi: 10.5009/gnl15573
Since its discovery in 1989, hepatitis C virus (HCV) has been intensively investigated to understand its biology and develop effective antiviral therapies. The efforts of the previous 25 years have... -
- CITED
-
- Close
- SHARE
-
- Close
- Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus
-
Tamai H, Ida Y, Kawashima , Shingaki N, Shimizu R, Moribata K, Nasu T, Maekita T, Iguchi M, Kato J, Nakao T, Kitano M
- KMID: 2412236
- Gut Liver.
- 2017 Jul;11(4):551-558.
- doi: 10.5009/gnl16525
BACKGROUND/AIMS: The present study aimed to evaluate the safety and efficacy of simeprevir-based triple therapy with reduced doses of pegylated interferon (PEG-IFN) and ribavirin for interferon (IFN) ineligible patients, such... -
- CITED
-
- Close
- SHARE
-
- Close
- A 2015 roadmap for the management of hepatitis C virus infections in Asia
-
Lim SG, Dan YY
- KMID: 2366001
- Korean J Intern Med.
- 2015 Jul;30(4):423-433.
- doi: 10.3904/kjim.2015.30.4.423
The prevalence of hepatitis C virus (HCV) in Asia is 0.5% to 4.7%, with three different genotypes predominating, depending on the geographic region: genotype 1b in East Asia, genotype 3... -
- CITED
-
- Close
- SHARE
-
- Close
- Effectiveness and Complications of Combination Therapy with Interferon Alpha and Ribavirin in Patients with Chronic Hepatitis C
-
Hwang SY, Lee HJ, Park KT, Kim KY, Lee SM, Park CW, Kim TO, Kim GH, Heo J, Kang DH, Song GA, Cho M, Cho BM
- KMID: 782839
- Korean J Gastroenterol.
- 2007 Mar;49(3):166-172.
BACKGROUND/AIMS: The effectiveness of combination therapy with conventional or pegylated interferon alpha and ribavirin in patients with chronic hepatitis C is well understood. However, the profound investigation about complications of... -
- CITED
-
- Close
- SHARE
-
- Close
